右雷佐生对急性髓系白血病患者左心室收缩功能及治疗结局的影响:儿童肿瘤协作组报告
该多中心研究纳入2011至2016年儿童肿瘤协作组AAML1031试验中无高等位基因比FLT3/ITD的儿童急性髓系白血病患者,比较右雷佐生暴露与未暴露者的左心室收缩功能障碍、射血分数与缩短分数变化、5年无事件生存、总生存及治疗相关死亡率。结果显示右雷佐生暴露者左心室收缩功能障碍风险更低(26.5% vs 42.2%;HR 0.55;95%CI 0.36-0.86;P=0.009),5年无事件生存与总生存无显著差异,治疗相关死亡率有降低趋势(5.7% vs 12.7%;P=0.068)。
要点
- 右雷佐生暴露者左心室收缩功能障碍发生率26.5%,未暴露者42.2%(HR 0.55;95%CI 0.36-0.86;P=0.009)。
- 右雷佐生暴露者5年无事件生存49.0% vs 未暴露者45.1%(P=0.534),无显著差异。
- 右雷佐生暴露者5年总生存65.0% vs 未暴露者61.9%(P=0.613),无显著差异。
核心结论
- 右雷佐生在不影响无事件生存和总生存、不增加非心脏毒性情况下保护心脏功能,应考虑用于儿童急性髓系白血病前线治疗中的心脏保护。
研究设计与样本
- 多中心研究,纳入2011至2016年儿童肿瘤协作组AAML1031试验中全部无高等位基因比FLT3/ITD的儿童急性髓系白血病患者,中位随访3.5年。
- 共1014例患者纳入分析,96例在每个蒽环类疗程均暴露于右雷佐生,918例从未暴露。
- 右雷佐生由主治医师酌情给药并记录于每个疗程;每疗程后及随访定期记录射血分数和缩短分数。
- 按方案,若左心室收缩功能障碍定义为缩短分数<28%或射血分数<55%,则应停用蒽环类药物。
主要发现
- 右雷佐生暴露者较未暴露者在各疗程中射血分数和缩短分数下降显著更小。
- 右雷佐生暴露者左心室收缩功能障碍风险更低:26.5% vs 42.2%(HR 0.55;95%CI 0.36-0.86;P=0.009)。
- 右雷佐生暴露者与未暴露者5年无事件生存相似:49.0% vs 45.1%(P=0.534)。
- 右雷佐生暴露者与未暴露者5年总生存相似:65.0% vs 61.9%(P=0.613)。
- 右雷佐生暴露者有治疗相关死亡率降低的提示:5.7% vs 12.7%(P=0.068)。
关键数值与推荐
- 左心室收缩功能障碍定义:缩短分数<28%或射血分数<55%。
- 右雷佐生暴露者左心室收缩功能障碍26.5% vs 未暴露者42.2%(HR 0.55;95%CI 0.36-0.86;P=0.009)。
- 右雷佐生暴露者5年无事件生存49.0% vs 未暴露者45.1%(P=0.534)。
- 右雷佐生暴露者5年总生存65.0% vs 未暴露者61.9%(P=0.613)。
- 右雷佐生暴露者治疗相关死亡率5.7% vs 未暴露者12.7%(P=0.068)。
临床怎么用
- 作者结论认为右雷佐生应被考虑用于儿童急性髓系白血病前线治疗中的心脏保护。
局限性
- 右雷佐生由主治医师酌情给药,非随机分配。
- 治疗相关死亡率降低仅为提示性(5.7% vs 12.7%;P=0.068),未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether dexrazoxane provides effective cardioprotection during frontline treatment of pediatric acute myeloid leukemia (AML) without increasing relapse risk or noncardiac toxicities of the chemotherapy regimens. PATIENTS AND METHODS: This was a multicenter study of all pediatric patients with AML without high allelic ratio FLT3/ITD treated in the Children's Oncology Group trial AAML1031 between 2011 and 2016. Median follow-up was 3.5 years. Dexrazoxane was administered at the discretion of treating physicians and documented at each course. Ejection fraction (EF) and shortening fraction (SF) were recorded after each course and at regular intervals in follow-up. Per protocol, anthracyclines were to be withheld if there was evidence of left ventricular systolic dysfunction (LVSD) defined as SF < 28% or EF < 55%. Occurrence of LVSD, trends in EF and SF, 5-year event-free survival (EFS) and overall survival (OS), and treatment-related mortality (TRM) were compared by dexrazoxane exposure. RESULTS: A total of 1,014 patients were included in the analyses; 96 were exposed to dexrazoxane at every anthracycline course, and 918 were never exposed. Distributions of sex, age, race, presenting WBC count, risk group, treatment arm, and compliance with cardiac monitoring were similar for dexrazoxane-exposed and -unexposed patients. Dexrazoxane-exposed patients had significantly smaller EF and SF declines than unexposed patients across courses and a lower risk for LVSD (26.5% v 42.2%; hazard ratio, 0.55; 95% CI, 0.36 to 0.86; P = .009). Dexrazoxane-exposed patients had similar 5-year EFS (49.0% v 45.1%; P = .534) and OS (65.0% v 61.9%; P = .613) to those unexposed; however, there was a suggestion of lower TRM with dexrazoxane (5.7% v 12.7%; P = .068). CONCLUSION: Dexrazoxane preserved cardiac function without compromising EFS and OS or increasing noncardiac toxicities. Dexrazoxane should be considered for cardioprotection during frontline treatment of pediatric AML.
引用
- Getz KD, Sung L, Alonzo TA, et al. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020. PMID: 32343641. doi:10.1200/JCO.19.02856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。